⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14961820 | 1.00 | — | — | |
| SCHEMBL14961821 | 1.00 | — | — | |
| SCHEMBL5983613 | 0.94 | — | — | |
| SCHEMBL6755980 | 0.91 | IDO1 (0.31) | — | |
| SCHEMBL12855376 | 0.91 | IDO1 (0.31) | — | |
| SCHEMBL2345052 | 0.87 | — | — | |
| SCHEMBL12191508 | 0.87 | — | — | |
| SCHEMBL12191506 | 0.87 | — | — | |
| SCHEMBL12333584 | 0.82 | — | — | |
| SCHEMBL13764905 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| CN-103391939-A | Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes | EPIZYME INC | 2013-11-13 | — | — | CN | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8063033-B2 | Therapeutic beta-lactams | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8044092-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-1844232-B1 | CHEMICAL ACTIVATION OF AN OSMOTIC ACTUATOR OR AN OSMOTIC MOTOR | UNIV JOSEPH FOURIER (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100317872-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7799821-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7674786-B2 | Therapeutic β-lactams | ALLERGAN, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090186866-A1 | THERAPEUTIC BETA-LACTAMS | ALLERGAN, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20080113943-A1 | Therapeutic Beta-Lactams | ALLERGAN, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |